107 related articles for article (PubMed ID: 27396030)
1. NCCN Awarded $2 Million in Research Funding from Infinity Pharmaceuticals to Study Duvelisib in Hematologic Malignancies.
J Natl Compr Canc Netw; 2016 Mar; 14(3):xl. PubMed ID: 27396030
[No Abstract] [Full Text] [Related]
2. Duvelisib, a new PI3K inhibitor for lymphoid malignancies.
Lamanna N
Clin Adv Hematol Oncol; 2020 Oct; 18(10):606-608. PubMed ID: 33201865
[No Abstract] [Full Text] [Related]
3. Idelalisib for chronic lymphocytic leukemia.
Brown JR
Clin Adv Hematol Oncol; 2014 Dec; 12(12):846-8. PubMed ID: 25674842
[No Abstract] [Full Text] [Related]
4. [CAL-101,a novel agent of targeted therapy in hematological malignancies].
Li CJ; Zhang Q; Zhang YZ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Apr; 22(2):530-3. PubMed ID: 24763037
[TBL] [Abstract][Full Text] [Related]
5. More on Merkel-Cell Carcinoma.
Blom A; Saiag P
N Engl J Med; 2016 Feb; 374(5):494-5. PubMed ID: 26840149
[No Abstract] [Full Text] [Related]
6. More on Merkel-Cell Carcinoma.
Shiver MB; Mahmoud F; Gao L
N Engl J Med; 2016 Feb; 374(5):495. PubMed ID: 26840148
[No Abstract] [Full Text] [Related]
7. Response to Idelalisib in a Patient with Stage IV Merkel-Cell Carcinoma.
Shiver MB; Mahmoud F; Gao L
N Engl J Med; 2015 Oct; 373(16):1580-2. PubMed ID: 26466009
[No Abstract] [Full Text] [Related]
8. The extinction of drugs for clinical research: Can the ECNP medicines chest save them?
Nutt D; Kilpatrick G; Hayes A
Eur Neuropsychopharmacol; 2014 Apr; 24(4):487-90. PubMed ID: 24508534
[No Abstract] [Full Text] [Related]
9. Population pharmacokinetic modeling of idelalisib, a novel PI3Kδ inhibitor, in healthy subjects and patients with hematologic malignancies.
Jin F; Gao Y; Zhou H; Fang L; Li X; Ramanathan S
Cancer Chemother Pharmacol; 2016 Jan; 77(1):89-98. PubMed ID: 26645408
[TBL] [Abstract][Full Text] [Related]
10. 28th Annual JPMorgan Healthcare Conference--Affymax and Infinity Pharmaceuticals.
Croasdell G; Mason VL
IDrugs; 2010 Mar; 13(3):142-4. PubMed ID: 20191425
[TBL] [Abstract][Full Text] [Related]
11. First PI3k inhibitor launches into crowded hematology markets.
Morrison C
Nat Biotechnol; 2014 Oct; 32(10):963-4. PubMed ID: 25299893
[No Abstract] [Full Text] [Related]
12. Sources of bias in the economic analysis of new drugs.
Rakatansky H
JAMA; 2000 Mar; 283(11):1424. PubMed ID: 10732928
[No Abstract] [Full Text] [Related]
13. Sources of bias in the economic analysis of new drugs.
Prendergast MM
JAMA; 2000 Mar; 283(11):1424. PubMed ID: 10732927
[No Abstract] [Full Text] [Related]
14. Sources of bias in the economic analysis of new drugs.
Le Pen C
JAMA; 2000 Mar; 283(11):1423-4. PubMed ID: 10732926
[No Abstract] [Full Text] [Related]
15. Should we clean up the reputation of "dirty drugs"?
Pierce G
Can J Physiol Pharmacol; 2012 Oct; 90(10):1333-4. PubMed ID: 23020177
[No Abstract] [Full Text] [Related]
16. Mammalian target of rapamycin as a target in hematological malignancies.
Abdel-Karim IA; Giles FJ
Curr Probl Cancer; 2008; 32(4):161-77. PubMed ID: 18655914
[No Abstract] [Full Text] [Related]
17. Support for trials of promising medications through the Pharmaceutical Benefits Scheme.
Flecknoe-Brown SC
Med J Aust; 1995 Apr; 162(8):447. PubMed ID: 7746193
[No Abstract] [Full Text] [Related]
18. Sources of bias in the economic analysis of new drugs. Health Outcomes Committee Pharmaceutical Research and Manufacturers of America, Washington, DC.
Gagnon JP
JAMA; 2000 Mar; 283(11):1423; author reply 1424. PubMed ID: 10732925
[No Abstract] [Full Text] [Related]
19. Duvelisib in indolent non-Hodgkin lymphoma.
Das M
Lancet Oncol; 2019 Mar; 20(3):e138. PubMed ID: 30799261
[No Abstract] [Full Text] [Related]
20. Investigational antibody-drug conjugates for hematological malignancies.
Polson AG; Ho WY; Ramakrishnan V
Expert Opin Investig Drugs; 2011 Jan; 20(1):75-85. PubMed ID: 21142808
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
